KEROS THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect the three (3) nominees for Class II director named below to hold office until the 2028 Annual Meeting of Stockholders: Alpna Seth, Ph.D.

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alpna Seth, Ph.D.”): 15,091,438 for, 8,618,834 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 6,891,649 for, 1,233,857 withheld.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: To elect the three (3) nominees for Class II director named below to hold office until the 2028 Annual Meeting of Stockholders: Mary Ann Gray, Ph.D.

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mary Ann Gray, Ph.D.”): 13,703,361 for, 10,006,911 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 58% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 6,891,649 for, 1,233,857 withheld.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: To elect the three (3) nominees for Class II director named below to hold office until the 2028 Annual Meeting of Stockholders: Ran Nussbaum

KEROS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ran Nussbaum”): 22,703,180 for, 5,304,100 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the three persons listed below as directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 6,874,603 for, 1,250,903 withheld.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement.

KEROS THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 18,580,618 for, 4,166,083 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3.”
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of KEROS THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “APPROVAL OF COMPENSATION OF EXECUTIVE OFFICERS” (4 managers, 187,500 for, 928,657 against); “Advisory Vote to Ratify Named Executive Officers' Compensation” (4 managers, 27,572 for, 26,505 against).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 48 managers: 8,025,264 for, 100,242 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 114 managers: 11,628,059 for, 4,727,859 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.

KEROS THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2025”): 26,436,418 for, 217,655 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2025 The Company's stockholders approved Proposal 2.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 8,125,506 for.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.